RSMDF (ResMed) Quality Rank


RSMDF ResMed Inc RSMDF
94 GF Score
Price $16.72
GF Value $23.97
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

ResMed Quality Rank Related Terms

RSMDF
94GF Score
ResMed Inc RSMDF
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ResMed (RSMDF) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of $16.72 is trading 30.2% below its estimated GF Value™ of $23.97. GuruFocus considers ResMed to be Significantly Undervalued.

Key valuation signals for RSMDF:

  • Quality Rank:
  • GF Value™: $23.97 vs. price of $16.72 (30.2% below fair value)
  • GF Score™: 94/100 with 1 warning sign

No single metric tells the full story. See the RSMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
94GF Score

Get the complete analysis for RSMDF

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.72
Price
$23.97
GF Value